Journal article · 2023 · Open access
Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis
RMD Open, 9(4), e003630 · Published 1 November 2023 · DOI 10.1136/rmdopen-2023-003630
In brief
“Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis” is a 2023 journal article by Hannah Bower and 4 co-authors, published in RMD Open. OpenAlex counts 26 citations as of 19 November 2026, which puts it in the top 2% of works published in 2023 by citations. It is open access under a CC BY-NC licence: the full text is free to read at RMD Open.
- Citations
- 26
- Most cited in
- 2026 (11)
- Field-weighted impact
- 4.17
- References
- 27
- Authors
- 5
Abstract
OBJECTIVES: To compare the incidence of cardiovascular (CV) events in rheumatoid arthritis (RA) treated with janus kinase inhibitors (JAKi), tumour necrosis factor inhibitors (TNFi), or other biological disease-modifying antirheumatic drugs (bDMARDs), in clinical practice, and to contextualise these findings by comparing to the Swedish RA population and general population at large. METHODS: Patients with RA initiating JAKi, TNFi and non-TNFi bDMARDs were identified in the Swedish Rheumatology Quality Register between 2016 and 2021. Through linkages to national registers, a cohort of patients with RA, general population comparators, as well as covariates and incident major acute CV event (MACE, including myocardial infarction, stroke and fatal CV events) were identified until 2022. Crude and age-sex standardised rates were calculated and HRs estimated from multivariable Cox regression models using TNFi as reference. RESULTS: We identified 13 492 patients with RA initiating a JAKi, non-TNFi bDMARD or TNFi treatment. Among 3037 JAKi-initiators, 59 MACE events were observed. The age-sex standardised rates for MACE were similar in the JAKi (0.88 per 100 person years) and TNFi (0.91) cohorts. Fully adjusted models showed no increased rate of MACE with JAKi (HR=0.71, 95% CI 0.51 to 0.99), or non-TNFi bDMARD (HR=0.98; 95% CI 0.78 to 1.23) in comparison to TNFi. We found no evidence that this HR changed over time since treatment initiation. In a CV-enriched subset, we observed higher rates but similar HRs. CONCLUSIONS: As used in present clinical practice in Sweden, we found no evidence that CV risk is higher with JAKis than TNFis in RA.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Bower, H., Frisell, T., Di Giuseppe, D., Delcoigne, B., & Askling, J. (2023). Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis. RMD Open, 9(4), e003630. https://doi.org/10.1136/rmdopen-2023-003630
MLA 9
Bower, Hannah, et al. “Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.” RMD Open, vol. 9, no. 4, 2023, p. e003630. https://doi.org/10.1136/rmdopen-2023-003630.
Chicago
Bower, Hannah, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, and Johan Askling. 2023. “Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.” RMD Open 9 (4): e003630. https://doi.org/10.1136/rmdopen-2023-003630.
Harvard
Bower, H. et al. (2023) ‘Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis’, RMD Open, 9(4), p. e003630. doi:10.1136/rmdopen-2023-003630.
IEEE
H. Bower, T. Frisell, D. Di Giuseppe, B. Delcoigne, and J. Askling, “Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis,” RMD Open, vol. 9, no. 4, p. e003630, 2023, doi: 10.1136/rmdopen-2023-003630.
BibTeX
@article{bower2023comparative,
title = {{Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis}},
author = {Bower, Hannah and Frisell, Thomas and Di Giuseppe, Daniela and Delcoigne, Bénédicte and Askling, Johan},
journal = {RMD Open},
year = {2023},
volume = {9},
number = {4},
pages = {e003630},
doi = {10.1136/rmdopen-2023-003630},
url = {https://doi.org/10.1136/rmdopen-2023-003630}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 7 | |
| 2025 | 8 | |
| 2026 | 11 |
Its field-weighted citation impact is 4.17: it has been cited 4.17 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- rheumatoid arthritis
- JAK inhibitors
- tumor necrosis factor inhibitors
- biologic DMARDs
- cardiovascular safety
- major adverse cardiovascular events
- myocardial infarction
- stroke
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Bower, H., Frisell, T., Di Giuseppe, D., Delcoigne, B., & Askling, J. (2023). Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis. RMD Open, 9(4), e003630. https://doi.org/10.1136/rmdopen-2023-003630
How many times has this paper been cited?
26 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at RMD Open: sign in and open the PDF from this page.
Who wrote this paper?
Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, Johan Askling.
What is the DOI of this paper?
10.1136/rmdopen-2023-003630, permanently at https://doi.org/10.1136/rmdopen-2023-003630. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.